Multiple sclerosis, gut microbiota and permeability: Role of tryptophan catabolites, depression and the driving down of local melatonin

Moses Rodriguez, Bharath Wootla, George Anderson

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.

Original languageEnglish (US)
Pages (from-to)6134-6141
Number of pages8
JournalCurrent Pharmaceutical Design
Volume22
Issue number40
DOIs
StatePublished - 2016

Fingerprint

Melatonin
Tryptophan
Multiple Sclerosis
Permeability
Depression
Gastrointestinal Microbiome
Biological Phenomena
Th17 Cells
Biological Factors
Genetic Predisposition to Disease
Neurodegenerative Diseases
Fatigue
Serotonin
Oxidative Stress
Cell Proliferation
Pediatrics
Recurrence
Pain

Keywords

  • Depression
  • Gut microbiota
  • Gut permeability
  • Immune inflammation
  • Melatonin
  • Multiple sclerosis
  • Oxidative stress
  • Pathophysiology
  • Serotonin
  • Th17

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Multiple sclerosis, gut microbiota and permeability : Role of tryptophan catabolites, depression and the driving down of local melatonin. / Rodriguez, Moses; Wootla, Bharath; Anderson, George.

In: Current Pharmaceutical Design, Vol. 22, No. 40, 2016, p. 6134-6141.

Research output: Contribution to journalReview article

@article{9aae4a659f9048d3bcb7f56d74e94d35,
title = "Multiple sclerosis, gut microbiota and permeability: Role of tryptophan catabolites, depression and the driving down of local melatonin",
abstract = "Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.",
keywords = "Depression, Gut microbiota, Gut permeability, Immune inflammation, Melatonin, Multiple sclerosis, Oxidative stress, Pathophysiology, Serotonin, Th17",
author = "Moses Rodriguez and Bharath Wootla and George Anderson",
year = "2016",
doi = "10.2174/1381612822666160915160520",
language = "English (US)",
volume = "22",
pages = "6134--6141",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "40",

}

TY - JOUR

T1 - Multiple sclerosis, gut microbiota and permeability

T2 - Role of tryptophan catabolites, depression and the driving down of local melatonin

AU - Rodriguez, Moses

AU - Wootla, Bharath

AU - Anderson, George

PY - 2016

Y1 - 2016

N2 - Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.

AB - Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.

KW - Depression

KW - Gut microbiota

KW - Gut permeability

KW - Immune inflammation

KW - Melatonin

KW - Multiple sclerosis

KW - Oxidative stress

KW - Pathophysiology

KW - Serotonin

KW - Th17

UR - http://www.scopus.com/inward/record.url?scp=85007543270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007543270&partnerID=8YFLogxK

U2 - 10.2174/1381612822666160915160520

DO - 10.2174/1381612822666160915160520

M3 - Review article

C2 - 27634184

AN - SCOPUS:85007543270

VL - 22

SP - 6134

EP - 6141

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 40

ER -